BridgeBio Oncology Therapeutics launches with $200m funding
BridgeBio Pharma has announced the launch of BridgeBio Oncology Therapeutics (BBOT), supported by $200m of private external capital. The investment will expedite the development of the company’s precision oncology pipeline, focusing on new cancer …